Telo Genomics Cash And Equivalents vs. Total Debt
| TDSGF Stock | USD 0.07 0.01 13.58% |
For Telo Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Telo Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Telo Genomics Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Telo Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Telo Genomics Corp over time as well as its relative position and ranking within its peers.
Telo |
Telo Genomics Corp Total Debt vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth. Telo Genomics Corp is rated below average in cash and equivalents category among its peers. It also is rated below average in total debt category among its peers making up about 0.01 of Total Debt per Cash And Equivalents. The ratio of Cash And Equivalents to Total Debt for Telo Genomics Corp is roughly 67.25 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.Telo Total Debt vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Telo Genomics |
| = | 2.69 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Telo Genomics |
| = | 40 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Telo Total Debt vs Competition
Telo Genomics Corp is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 5.38 Billion. Telo Genomics adds roughly 40,000 in total debt claiming only tiny portion of equities under Health Care industry.
Telo Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Telo Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Telo Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Telo Genomics' change in net profit over the period of time. It can combine multiple indicators of Telo Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada. TELO GENOMICS is traded on OTC Exchange in the United States.
Telo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Telo Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Telo Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Telo Genomics' important profitability drivers and their relationship over time.
Use Telo Genomics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telo Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telo Genomics will appreciate offsetting losses from the drop in the long position's value.Telo Genomics Pair Trading
Telo Genomics Corp Pair Trading Analysis
The ability to find closely correlated positions to Telo Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telo Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telo Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telo Genomics Corp to buy it.
The correlation of Telo Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telo Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telo Genomics Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telo Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Telo Genomics position
In addition to having Telo Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Information Technology ETFs Thematic Idea Now
Information Technology ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Information Technology ETFs theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Information Technology ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Telo OTC Stock
To fully project Telo Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Telo Genomics Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Telo Genomics' income statement, its balance sheet, and the statement of cash flows.